PMID- 35967307
OWN - NLM
STAT- MEDLINE
DCOM- 20220816
LR  - 20220818
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of 
      Iguratimod Combined With Other Therapies for Sjogren's Syndrome.
PG  - 924730
LID - 10.3389/fimmu.2022.924730 [doi]
LID - 924730
AB  - OBJECTIVE: To explore the efficacy and safety of Iguratimod intervention in 
      Primary Sjogren's syndrome (pSS). METHODS: Many databases were searched to 
      collect the RCTs. Three independent reviewers extracted data and assessed the 
      quality of the studies based on the Cochrane Handbook. The statistical analysis 
      was done by RevMan 5.3 and STATA. The quality of evidence was evaluated by GRADE 
      tool. RESULTS: Twenty-nine RCTs with 2258 participants were included in this 
      review. The meta-analysis shows that: iguratimod experiment group can reduce the 
      ESSPRI score (WMD -1.93 [-2.33, -1.52], P<0.00001), ESSDAI score (WMD -1.39 
      [-1.81, -0.98], P<0.00001), Schirmer's test (WMD 1.77 [0.85, 2.70], P=0.0002), RF 
      (WMD -5.78 [-7.59, -3.97], P<0.00001), and decrease the ESR level (WMD -7.05 
      [-9.84, -4.26], P<0.00001). Meanwhile, the summary result showed the addiction of 
      Iguratimod may not increase the adverse events. The adverse events were mainly 
      gastrointestinal discomfort, abnormal liver function, and rash and itching. The 
      quality of evidence of adverse events was moderate. Referring to minimal 
      clinically important difference (MCID), the improvement of ESSPRI is clinically 
      significant, and the improvement of ESSDAI for patients older than 60 years old 
      may be clinically significant. CONCLUSION: Based on current evidence, iguratimod 
      can effectively reduce ESSPRI score, ESSDAI score, Schirmer's test score and 
      decrease systemic inflammatory response (such as ESR level and RF level) without 
      increasing the probability of adverse events. The recommended course of treatment 
      is at least 12 weeks. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/prospero/display_record.php?, identifier 
      CRD42020220770.
CI  - Copyright (c) 2022 Zeng, He, Yang, Hao, Yu and Chen.
FAU - Zeng, Liuting
AU  - Zeng L
AD  - Department of Rheumatology and Clinical Immunology, Peking Union Medical College 
      Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      National Clinical Research Center for Dermatologic and Immunologic Diseases 
      (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of 
      Education, Beijing, China.
FAU - He, Qi
AU  - He Q
AD  - People's Hospital of Ningxiang City, Ningxiang City, China.
FAU - Yang, Kailin
AU  - Yang K
AD  - Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western 
      Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan 
      University of Chinese Medicine, Changsha City, China.
FAU - Hao, Wensa
AU  - Hao W
AD  - Department of Rheumatology and Clinical Immunology, Peking Union Medical College 
      Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      National Clinical Research Center for Dermatologic and Immunologic Diseases 
      (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of 
      Education, Beijing, China.
FAU - Yu, Ganpeng
AU  - Yu G
AD  - Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western 
      Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan 
      University of Chinese Medicine, Changsha City, China.
FAU - Chen, Hua
AU  - Chen H
AD  - Department of Rheumatology and Clinical Immunology, Peking Union Medical College 
      Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 
      National Clinical Research Center for Dermatologic and Immunologic Diseases 
      (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of 
      Education, Beijing, China.
LA  - eng
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20220728
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Chromones)
RN  - 0 (Sulfonamides)
RN  - 4IHY34Y2NV (iguratimod)
SB  - IM
MH  - Chromones
MH  - Humans
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic
MH  - *Sjogren's Syndrome/drug therapy
MH  - Sulfonamides
PMC - PMC9367640
OTO - NOTNLM
OT  - Primary Sjogren's syndrome
OT  - iguratimod
OT  - meta-analysis
OT  - randomized controlled trials
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/16 06:00
MHDA- 2022/08/17 06:00
PMCR- 2022/01/01
CRDT- 2022/08/15 03:56
PHST- 2022/04/20 00:00 [received]
PHST- 2022/05/31 00:00 [accepted]
PHST- 2022/08/15 03:56 [entrez]
PHST- 2022/08/16 06:00 [pubmed]
PHST- 2022/08/17 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.924730 [doi]
PST - epublish
SO  - Front Immunol. 2022 Jul 28;13:924730. doi: 10.3389/fimmu.2022.924730. eCollection 
      2022.